Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 372

Similar articles for PubMed (Select 17475817)

1.

Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors.

Feringa HH, Karagiannis SE, Chonchol M, Vidakovic R, Noordzij PG, Elhendy A, van Domburg RT, Welten G, Schouten O, Bax JJ, Berl T, Poldermans D.

J Am Soc Nephrol. 2007 Jun;18(6):1872-9. Epub 2007 May 2.

2.

Glycemic control, lipid-lowering treatment, and prognosis in diabetic patients with peripheral atherosclerotic disease.

Feringa HH, Karagiannis SE, Vidakovic R, Elhendy A, Schouten O, Boersma E, Bax JJ, Poldermans D.

Ann Vasc Surg. 2007 Nov;21(6):780-9.

PMID:
17980797
3.

The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease.

Feringa HH, Karagiannis SE, van Waning VH, Boersma E, Schouten O, Bax JJ, Poldermans D.

J Vasc Surg. 2007 May;45(5):936-43. Epub 2007 Mar 13.

4.

Prognostic significance of declining ankle-brachial index values in patients with suspected or known peripheral arterial disease.

Feringa HH, Karagiannis SE, Schouten O, Vidakovic R, van Waning VH, Boersma E, Welten G, Bax JJ, Poldermans D.

Eur J Vasc Endovasc Surg. 2007 Aug;34(2):206-13. Epub 2007 May 4.

5.

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.

Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G.

Am J Kidney Dis. 2000 Jun;35(6):1155-65.

PMID:
10845831
6.

Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease.

Feringa HH, van Waning VH, Bax JJ, Elhendy A, Boersma E, Schouten O, Galal W, Vidakovic RV, Tangelder MJ, Poldermans D.

J Am Coll Cardiol. 2006 Mar 21;47(6):1182-7. Epub 2006 Feb 23.

7.

Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease.

van Gestel YR, Hoeks SE, Sin DD, Simsek C, Welten GM, Schouten O, Stam H, Mertens FW, van Domburg RT, Poldermans D.

Am J Cardiol. 2008 Jul 15;102(2):192-6. doi: 10.1016/j.amjcard.2008.03.038. Epub 2008 May 28.

PMID:
18602520
8.

Renal dysfunction predicts long-term mortality in patients with lower extremity arterial disease.

Pasqualini L, Schillaci G, Pirro M, Vaudo G, Siepi D, Innocente S, Ciuffetti G, Mannarino E.

J Intern Med. 2007 Dec;262(6):668-77. Epub 2007 Oct 1.

PMID:
17908164
9.

Evaluation of medical treatment for peripheral arterial disease in Chinese high-risk patients.

Hasimu B, Li J, Yu J, Ma Y, Zhao M, Nakayama T, Ma W, Yang J, Zheng L, Li X, Luo Y, Xu Y, Zhang L, Zou L, Xiao W, Han Y, Hu D.

Circ J. 2007 Jan;71(1):95-9.

10.

HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.

Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO.

Kidney Int. 2002 Jan;61(1):297-304.

11.

Elderly patients undergoing major vascular surgery: risk factors and medication associated with risk reduction.

Feringa HH, Bax JJ, Karagiannis SE, Noordzij P, van Domburg R, Klein J, Poldermans D.

Arch Gerontol Geriatr. 2009 Jan-Feb;48(1):116-20. doi: 10.1016/j.archger.2007.11.003. Epub 2008 Jan 4.

PMID:
18177954
12.

The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.

Jafar TH, Schmid CH, Stark PC, Toto R, Remuzzi G, Ruggenenti P, Marcantoni C, Becker G, Shahinfar S, De Jong PE, De Zeeuw D, Kamper AL, Strangaard S, Levey AS.

Nephrol Dial Transplant. 2003 Oct;18(10):2047-53.

13.

Usefulness of hypertensive blood pressure response during a single-stage exercise test to predict long-term outcome in patients with peripheral arterial disease.

de Liefde II, Hoeks SE, van Gestel YR, Bax JJ, Klein J, van Domburg RT, Poldermans D.

Am J Cardiol. 2008 Oct 1;102(7):921-6. doi: 10.1016/j.amjcard.2008.05.032. Epub 2008 Jul 9.

PMID:
18805123
14.

Long-term effects of upstream therapy on paroxysmal atrial fibrillation in patients without overt heart diseases.

Hirayama Y, Atarashi H, Kobayashi Y, Iwasaki Y, Miyauchi Y, Ohara T, Yashima M, Katoh T, Mizuno K.

Int Heart J. 2009 Mar;50(2):141-51.

15.

Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort.

Zeymer U, Parhofer KG, Pittrow D, Binz C, Schwertfeger M, Limbourg T, Röther J.

Clin Res Cardiol. 2009 Apr;98(4):249-56. doi: 10.1007/s00392-009-0754-1. Epub 2009 Feb 16.

PMID:
19221687
17.

PAD as a risk factor for mortality among patients with elevated ABI--a clinical study.

Suominen V, Uurto I, Saarinen J, Venermo M, Salenius J.

Eur J Vasc Endovasc Surg. 2010 Mar;39(3):316-22. doi: 10.1016/j.ejvs.2009.12.003. Epub 2010 Jan 20.

18.

Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease.

Thatipelli MR, Pellikka PA, McBane RD, Rooke TW, Rosales GA, Hodge D, Herges RM, Wysokinski WE.

J Vasc Surg. 2007 Jul;46(1):62-70; discussion 70. Epub 2007 Jun 20.

20.

Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.

Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R.

J Am Soc Nephrol. 2006 Mar;17(3):889-99. Epub 2006 Feb 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk